Wednesday, March 05, 2025 | 11:14 AM ISTहिंदी में पढें

Home / Markets / News / AstraZeneca gains 5% on marketing nod to launch cancer drug in India

AstraZeneca gains 5% on marketing nod to launch cancer drug in India

The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.

pharma companies, immunology,vantage point, hospitals,science pharmaceuticals

Premium

Patients prefer better outcome to brand in new treatments, says report

SI Reporter Mumbai

Last Updated : Jun 22 2018 | 10:05 AM IST

AstraZeneca Pharma India was up 5% to Rs 1,416 on the BSE in early morning trade after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.

“The company has received import & market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses,” AstraZeneca Pharma India said in a press release.

Durvalumab provides a

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in